A study, aimed at determining whether an EGFR-targeted therapy combined with chemo-radiotherapy can improve local tumor control effectively, compared to cytotoxic agents or irradiation alone, will be published in May 2014, issue of Experimental Biology and Medicine. Dr. Haizhu Song and co-workers from Jinling Hospital and the Medical School of Nanjing University in China demonstrated that nimotuzumab could enhance chemo-radiosensitivity by promoting autophagic cell death in esophageal squamous carcinoma (ESCC) cells.
Nimotuzumab is a humanized anti-EGFR monoclonal antibody that inhibits EGF-stimulated receptor autophosphorylation and downstream signaling pathways. The majority of prior investigations have focused on the therapeutic effects of nimotuzumab on cancer cells including cell cycle arrest and the induction of apoptotic cell death. Dr. Chen's laboratory detected the autophagic activity of ESCC cells following a combination of nimotuzumab with paclitaxel, cis-platinum or external beam radiation. These results showed that autophagic activation by nimotuzumab facilitated the antitumor effects of cytotoxic agents and irradiation in ESCC cells with high expression of EGFR.
Chemotherapy
''Chemo'' means medicine or ''drug'', ''therapy'' means ''treatment''. Chemotherapy refers to the use of cytotoxic drugs in the treatment of cancer.
Therefore, nimotuzumab-combined therapy might be more beneficial for treating ESCC patients with a high level of EGFR expression and activation of autophagy; as part of a combined therapy or as an alternative approach to kill cancer cells more efficiently. "We hope that our study will be meaningful in gaining a mechanistic understanding of nimotuzumab-combined therapy and provide a potential strategy for improving therapeutic efficacy in esophageal squamous cell carcinoma," said Dr. Longbang Chen, corresponding author. Dr. Steven R. Goodman, Editor-in-Chief of Experimental Biology and Medicine said "Song and colleagues provide evidence, worth pursuing, that activation of autophagy by nimotuzumab may provide increased chemosensitivity and radiosensivity in ESCC".
Radiation Therapy Increases Risk for Heart Disease in Breast Cancer Patients
Radiotherapy ups the risk of heart disease in patients with breast cancer. The risk of heart disease
 Radiation HazardsIonizing radiation can damage living tissue in the human body. It strips away electrons from atoms breaks some chemical bonds. | Advertisement
|
Chemotherapy Drugs
Chemotherapy drugs perform like 'magic bullets' to destroy cancer cells in the body.
Latest Cancer News
